GHRP-2 + CJC-1295: separate inputs
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
— mL · U-100
Syringe markings measure volume. They are not IU of the compound. Calculations do not account for handling losses or product stability.
— mL · U-100
Syringe markings measure volume. They are not IU of the compound. Calculations do not account for handling losses or product stability.
Reference notes
Both source tables use microgram targets, but each vial still needs its own concentration calculation. Keep labels and results associated with their respective compounds.
The source describes the pair as a GHRP and GHRH combination. A shared schedule does not turn two vial amounts into one concentration.
| Compound / vial | 100 mcg | 200 mcg | 300 mcg |
|---|---|---|---|
| GHRP-2 / 5 mg | 4 | 8 | 12 |
| GHRP-2 / 10 mg | 2 | 4 | 6 |
| CJC-1295 no DAC / 2 mg | 10 | 20 | 30 |
| CJC-1295 no DAC / 5 mg | 4 | 8 | 12 |
| CJC-1295 no DAC / 10 mg | 2 | 4 | 6 |
Source & content review 2 notes
This is an original, concise draft. Full information and numerical parity with the source is not yet established.
Open source reference ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source contains comparative physiological claims and simultaneous-use guidance that have not been independently substantiated here.
Captured source values
{
"numericalFacts": []
}